Characteristics of 4 specific target antigens in adult acute lymphoblastic leukemia.
10.7534/j.issn.1009-2137.2013.02.006
- Author:
Zhong-Kun LIN
1
;
Run ZHANG
;
Zheng GE
;
Juan LIU
;
Yu-Jie WU
;
Xing GUO
;
Chun QIAO
;
Hai-Rong QIU
;
Jian-Yong LI
Author Information
1. Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province, China.
- Publication Type:Journal Article
- MeSH:
Adolescent;
Adult;
Aged;
Antigens, CD19;
immunology;
Antigens, CD20;
immunology;
Child;
Female;
Humans;
Immunophenotyping;
Male;
Middle Aged;
Precursor Cell Lymphoblastic Leukemia-Lymphoma;
genetics;
immunology;
Sialic Acid Binding Ig-like Lectin 2;
immunology;
Sialic Acid Binding Ig-like Lectin 3;
immunology;
Young Adult
- From:
Journal of Experimental Hematology
2013;21(2):289-295
- CountryChina
- Language:Chinese
-
Abstract:
This study was aimed to investigate clinical and prognostic significances of 4 target antigens (CD19, CD20, CD22 and CD33) for antibody-based immunotherapy and to evaluate the applications of these antibody-based target therapy to adult acute lymphoblastic leukemia (ALL). The immunophenotype of 220 adult patients with ALL were analyzed by four-color flow Cytometry, and cytogenetic and molecular parameters were detected by conventional cytogenetics, fluorescence in situ hybridization, real-time quantitative PCR, nested PCR and DNA sequencing. The results showed that CD19 positive (CD19(+)) cases were more in female (46.4% vs. 23.4%, P = 0.006), elderly patients aged > 60 years (14.4% vs. 2.1%, P = 0.022), CD33(+) co-expression cases (47.8% vs. 12.0%, P = 0.001) and genetic high-risk group (55.8% vs. 20.8%, P = 0.002) compared with CD19 negative (CD19(-)) cases; CD20(+) cases had lower co-expression of CD13 than CD20(-) cases (31.6% vs.67.1%, P = 0.000) and no significant prognostic indications for CD20(+) was observed; CD22(+) cases had higher relapse rate at 12-month than CD22(-) cases (93.9% vs.57.1%, P = 0.041) in B-ALL patients; CD33(+) cases had higher incidence of Ph(+) than CD33(-) cases (43.5% vs.19.4%, P = 0.007) and significantly correlated with Ph(+) (r = 0.261, P = 0.006). It is concluded that elucidation of the characteristics of the target antigens (CD19, CD20, CD22, CD33) used for antibody-based immunotherapy will help hematologists making the correct decision whether and when to use these antibody-based target therapies.
